Key Findings
A comprehensive review article published in MDPI details significant advancements in nanomaterial-based biosensors for the diagnosis of neuropsychiatric and neurodegenerative disorders. The review prominently highlights biofouling (non-specific adsorption in biofluids) as a critical challenge that leads to sensor interface passivation, inhibited electron transfer, signal drift, and reduced sensitivity and selectivity, thereby severely compromising long-term stability and reliability in clinical applications. To address this, innovative antifouling interface design strategies have been developed, including graphene FET biosensors modified with fluorinated covalent organic framework (F-COF) membranes and biomimetic coatings of erythrocyte and neuron membranes. These advancements enable graphene-based FET biosensors to quantitatively detect Aβ1-42 in undiluted plasma at an exceptionally low detection limit of 1.6 fM, and also facilitate the detection of stress markers like cortisol in sweat via wearable sensors, contributing significantly to personalized remote patient management.
Technical and Clinical Details
Nanomaterials, particularly graphene, carbon nanotubes, and quantum dots, dramatically enhance biosensor sensitivity and specificity due to their high surface area, excellent conductivity, and quantum size effects. The review highlights FET (field-effect transistor) biosensors built upon these materials. FET biosensors are highly sensitive because they detect changes in the electric field generated when biomolecules bind to the sensor surface. However, complex biological fluids like blood and cerebrospinal fluid (CSF) contain various proteins and cellular components that cause biofouling through non-specific adsorption onto the sensor surface. F-COF membranes and biomimetic coatings effectively suppress such non-specific adsorption, ensuring the long-term stability and reliability of the sensors. For example, the graphene FET biosensor capable of detecting Aβ1-42 (an Alzheimer’s biomarker) at a 1.6 fM detection limit paves the way for ultra-early disease diagnosis. Additionally, wearable sensors non-invasively measure cortisol in sweat, continuously monitoring stress levels and endocrine system status, thereby supporting the management of neuropsychiatric conditions.
Background and Industry Context
Neuropsychiatric and neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, depression, and schizophrenia are challenging to diagnose, and the identification of objective biomarkers, especially in early stages, is an urgent priority. Traditional diagnostic methods often rely on imaging and cognitive assessments, making early intervention difficult. Nanomaterial-based biosensors hold the potential to revolutionize early diagnosis, disease progression monitoring, and treatment efficacy evaluation by capturing changes at the molecular level for these conditions. Overcoming the biofouling problem is indispensable for these technologies to transition from laboratories to actual clinical settings and patients’ homes.
Strategic Significance and Outlook
The advancements in nanomaterial-based biosensors are expected to bring a paradigm shift to the diagnosis and management of neuropsychiatric and neurodegenerative diseases. Future developments will likely involve the creation of multiplex sensors capable of simultaneously detecting multiple neurological biomarkers, AI-integrated data analysis for predicting disease progression, and optimization of treatment strategies tailored to individual patients. Further miniaturization and improved comfort in wearable devices will enable continuous health monitoring outside hospitals, leading to a future where personalized remote patient management becomes standard. This promises significant improvements in early intervention and quality of life for patients with these conditions.
Comments